Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EBT (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed EBT for 10 consecutive years, with -$47.5 million as the latest value for Q4 2025.

  • Quarterly EBT fell 9.58% to -$47.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$196.0 million through Dec 2025, up 24.66% year-over-year, with the annual reading at -$196.0 million for FY2025, 24.67% up from the prior year.
  • EBT for Q4 2025 was -$47.5 million at Rhythm Pharmaceuticals, up from -$52.8 million in the prior quarter.
  • The five-year high for EBT was $65.8 million in Q1 2021, with the low at -$141.1 million in Q1 2024.
  • Average EBT over 5 years is -$44.5 million, with a median of -$44.5 million recorded in 2021.
  • The sharpest move saw EBT surged 292.47% in 2021, then crashed 179.89% in 2022.
  • Over 5 years, EBT stood at -$50.9 million in 2021, then rose by 16.44% to -$42.5 million in 2022, then increased by 2.49% to -$41.4 million in 2023, then dropped by 4.69% to -$43.4 million in 2024, then decreased by 9.58% to -$47.5 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$47.5 million, -$52.8 million, and -$46.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.